prednisone has been researched along with Panuveitis in 26 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Panuveitis: Inflammation in which both the anterior and posterior segments of the uvea are involved and a specific focus is not apparent. It is often severe and extensive and a serious threat to vision. Causes include systemic diseases such as tuberculosis, sarcoidosis, and syphilis, as well as malignancies. The intermediate segment of the eye is not involved.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the benefits of fluocinolone acetonide implant therapy versus systemic corticosteroid therapy supplemented (when indicated) with immunosuppression for intermediate uveitis, posterior uveitis, and panuveitis." | 9.20 | Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up ( Altaweel, MM; Drye, LT; Holbrook, JT; Jabs, DA; Kempen, JH; Sugar, EA; Thorne, JE, 2015) |
| "These results suggest that fluocinolone acetonide implant therapy is associated with a clinically important increased risk of glaucoma and cataract with respect to systemic therapy, suggesting that careful monitoring and early intervention to prevent glaucoma is warranted with implant therapy." | 9.20 | Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatmen ( , 2015) |
| "To compare the relative effectiveness of systemic corticosteroids plus immunosuppression when indicated (systemic therapy) versus fluocinolone acetonide implant (implant therapy) for noninfectious intermediate, posterior, or panuveitis (uveitis)." | 9.15 | Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. ( Altaweel, MM; Holbrook, JT; Jabs, DA; Kempen, JH; Louis, TA; Sugar, EA; Thorne, JE, 2011) |
| "To compare the benefits of fluocinolone acetonide implant therapy versus systemic corticosteroid therapy supplemented (when indicated) with immunosuppression for intermediate uveitis, posterior uveitis, and panuveitis." | 5.20 | Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up ( Altaweel, MM; Drye, LT; Holbrook, JT; Jabs, DA; Kempen, JH; Sugar, EA; Thorne, JE, 2015) |
| "These results suggest that fluocinolone acetonide implant therapy is associated with a clinically important increased risk of glaucoma and cataract with respect to systemic therapy, suggesting that careful monitoring and early intervention to prevent glaucoma is warranted with implant therapy." | 5.20 | Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatmen ( , 2015) |
| "To compare the relative effectiveness of systemic corticosteroids plus immunosuppression when indicated (systemic therapy) versus fluocinolone acetonide implant (implant therapy) for noninfectious intermediate, posterior, or panuveitis (uveitis)." | 5.15 | Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. ( Altaweel, MM; Holbrook, JT; Jabs, DA; Kempen, JH; Louis, TA; Sugar, EA; Thorne, JE, 2011) |
| "Chronic use of corticosteroids for the treatment of uveitis has been linked with drug-associated toxicity and adverse events (AEs)." | 2.84 | Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials. ( Bao, Y; Betts, KA; Camez, A; Joshi, A; Mittal, M; Suhler, EB; Tari, S; Thorne, JE, 2017) |
| "Sarcoidosis is a potentially life-threatening, multisystem, granulomatous disease that can present with cutaneous manifestations in patients." | 2.46 | Ichthyosiform sarcoidosis: A case report and review of the literature. ( George, DE; Hsu, S; Kelley, BP; LeLeux, TM, 2010) |
| "This study causally examined the dose-response relationship between oral corticosteroids (OCS) exposure and long-term complications among noninfectious uveitis adult patients in the United States." | 1.51 | Oral corticosteroid exposure and increased risk of related complications in patients with noninfectious intermediate, posterior, or panuveitis: Real-world data analysis. ( Chirikov, VV; Kwon, Y; Patel, D; Shah, R, 2019) |
| "Prednisone was tapered after 1 month." | 1.40 | Success with single-agent immunosuppression for multifocal choroidopathies. ( Godbold, J; Goldberg, NR; Jabs, DA; Lyu, T; Moshier, E, 2014) |
| "Optic neuropathy is an uncommon complication of MFCPU that may result in substantial visual morbidity." | 1.34 | Optic neuropathy complicating multifocal choroiditis and panuveitis. ( Dunn, JP; Jabs, DA; Kedhar, SR; Thorne, JE; Wittenberg, S, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (11.54) | 18.2507 |
| 2000's | 4 (15.38) | 29.6817 |
| 2010's | 18 (69.23) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Takhar, JS | 1 |
| Gonzales, JA | 1 |
| Suhler, EB | 2 |
| Thorne, JE | 4 |
| Mittal, M | 1 |
| Betts, KA | 1 |
| Tari, S | 1 |
| Camez, A | 1 |
| Bao, Y | 1 |
| Joshi, A | 1 |
| Boiché, M | 1 |
| Conart, JB | 1 |
| Angioi-Duprez, K | 1 |
| Medina, CA | 1 |
| Fajardo, A | 1 |
| Calderon, A | 1 |
| Aracena, M | 1 |
| Chirikov, VV | 1 |
| Shah, R | 1 |
| Kwon, Y | 1 |
| Patel, D | 1 |
| Faez, S | 1 |
| Lobo, AM | 1 |
| Unizony, SH | 1 |
| Stone, JH | 1 |
| Papaliodis, GN | 1 |
| Sobrin, L | 2 |
| Goldberg, NR | 1 |
| Lyu, T | 1 |
| Moshier, E | 1 |
| Godbold, J | 1 |
| Jabs, DA | 4 |
| Caso, F | 1 |
| Rigante, D | 1 |
| Vitale, A | 1 |
| Costa, L | 1 |
| Bascherini, V | 1 |
| Latronico, E | 1 |
| Franceschini, R | 1 |
| Cantarini, L | 1 |
| Kempen, JH | 2 |
| Altaweel, MM | 2 |
| Drye, LT | 1 |
| Holbrook, JT | 2 |
| Sugar, EA | 2 |
| Patel, A | 1 |
| Modjtahedi, BS | 1 |
| Freitag, SK | 1 |
| Kazlas, MA | 1 |
| Shantha, JG | 1 |
| Crozier, I | 1 |
| Varkey, JB | 1 |
| Kraft, CS | 1 |
| Lyon, GM | 1 |
| Mehta, AK | 1 |
| Carlson, RD | 1 |
| Hill, CE | 1 |
| Kumar, G | 1 |
| Debiec, MR | 1 |
| Patel, PS | 1 |
| Olsen, TW | 1 |
| Nussenblatt, RB | 1 |
| Martin, DF | 1 |
| Ströher, U | 1 |
| Uyeki, TM | 1 |
| Ribner, BS | 1 |
| Smith, JR | 1 |
| Yeh, S | 1 |
| Kelley, BP | 1 |
| George, DE | 1 |
| LeLeux, TM | 1 |
| Hsu, S | 1 |
| Payne, JF | 1 |
| Srivastava, SK | 1 |
| Wells, JR | 1 |
| Grossniklaus, HE | 1 |
| Bouomrani, S | 1 |
| Farah, A | 1 |
| Ayadi, N | 1 |
| Béji, M | 1 |
| Louis, TA | 1 |
| Matsumiya, W | 1 |
| Kusuhara, S | 1 |
| Yamada, Y | 1 |
| Azumi, A | 1 |
| Negi, A | 1 |
| Butler, NJ | 1 |
| Adán, A | 1 |
| Llorenç, V | 1 |
| Mesquida, M | 1 |
| Pelegrín, L | 1 |
| de Popa, DP | 1 |
| Smochină, S | 1 |
| Khurana, RN | 1 |
| Albini, T | 1 |
| Dea, MK | 1 |
| Rao, NA | 2 |
| Lim, JI | 1 |
| Wittenberg, S | 1 |
| Kedhar, SR | 1 |
| Dunn, JP | 1 |
| Ahmed, M | 1 |
| Niffenegger, JH | 1 |
| Jakobiec, FA | 1 |
| Ben-Arie-Weintrob, Y | 1 |
| Gion, N | 1 |
| Androudi, S | 1 |
| Folberg, R | 1 |
| Raizman, MB | 1 |
| Margo, CE | 1 |
| Smith, ME | 1 |
| McLean, IW | 1 |
| Caya, JG | 1 |
| Foster, CS | 1 |
| Bielory, L | 1 |
| Sohn, T | 1 |
| Rescigno, R | 1 |
| Tsai, JC | 1 |
| Forster, DJ | 1 |
| Ober, RR | 1 |
| Burgoyne, CF | 1 |
| Verstraeten, TC | 1 |
| Friberg, TR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter Uveitis Steroid Treatment (MUST) Trial[NCT00132691] | Phase 4 | 255 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00132691)
Timeframe: 24 months
| Intervention | percentage of eyes with uveitis at risk (Number) |
|---|---|
| Fluocinolone Acetonide Implant | 90.7 |
| Systemic Therapy | 44.9 |
Best-corrected visual acuity was measured as the number of letters read from standard logarithmic visual acuity charts by study-certified examiners who were masked to treatment. Visual acuity was measured at all study visits. The primary outcome was eye-specific change in visual acuity from baseline to 2-year follow-up. Positive change values indicate improved vision while negative change values indicate vision has gotten worse. A change of 7.5 letters is considered clinically meaningful. (NCT00132691)
Timeframe: 24 months
| Intervention | letters (Mean) |
|---|---|
| Flucinolone Acetonide Implant | 6.0 |
| Systemic Therapy | 3.2 |
The NEI-VFQ 25 measures the effect of visual disability/symptoms with generic health and task-oriented domains. The range for the composite score is 0 to 100; higher scores are associated with better visual function. A change of 4 to 6 points is considered to be a clinically meaningful difference. (NCT00132691)
Timeframe: 24 months
| Intervention | units on a scale (composite score) (Mean) |
|---|---|
| Fluocinolone Acetonide Implant | 11.44 |
| Systemic Therapy | 6.80 |
Self-reported health related QoL was measured with the SF 36 survey. The mental component score for the SF 36 is a summary measure of mental health primarily based on the social functioning, role emotional, mental health and vitality domains. The score is scaled to a population norm with a mean of 50 and standard deviation of 10. Higher scores represent better outcomes. The mean change in scores between baseline and 24 months was calculated for each treatment group. (NCT00132691)
Timeframe: 24 months
| Intervention | units on a scale (Mean) |
|---|---|
| Flucinolone Acetonide Implant | 2.55 |
| Systemic Therapy | -1.1 |
Self-reported health related QoL was measured with the SF 36 survey. The physical component score for the SF 36 is a summary measure of physical health primarily based on the physical functioning, role physical, bodily pain and general health domains of the survey. The score is scaled to a population norm with a mean of 50 and standard deviation of 10. Higher scores represent better outcomes. The mean change in scores between baseline and 24 months was calculated for each treatment group. A 3 to 5 point difference is considered to be clinically meaningful. (NCT00132691)
Timeframe: 24 months
| Intervention | units on a scale (Mean) |
|---|---|
| Flucinolone Acetonide Implant | 1.15 |
| Systemic Therapy | -1.8 |
(NCT00132691)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Flucinolone Acetonide Implant | 1.0 |
| Systemic Therapy | 3.6 |
Glaucoma was diagnosed by a glaucoma specialist through review of visual fields, clinical data, and fundus images. (NCT00132691)
Timeframe: 24 months
| Intervention | percentage of eyes with uveitis at risk (Number) |
|---|---|
| Fluocinolone Acetonide Implant | 16.5 |
| Systemic Therapy | 4.0 |
LDL greater than or equal to 160 mg/mL (NCT00132691)
Timeframe: 24 months
| Intervention | percentage of participants at risk (Number) |
|---|---|
| Flucinolone Acetonide Implant | 9.8 |
| Systemic Therapy | 11.0 |
(NCT00132691)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Flucinolone Acetonide Implant | 4.6 |
| Systemic Therapy | 10.5 |
(NCT00132691)
Timeframe: 24 months
| Intervention | percentage of eyes with uveitis at risk (Number) |
|---|---|
| Fluocinolone Acetonide Implant | 51.8 |
| Systemic Therapy | 15.5 |
(NCT00132691)
Timeframe: 24 months
| Intervention | percentage of eyes with uveitis at risk (Number) |
|---|---|
| Flucinolone Acetonide Implant | 53.1 |
| Systemic Therapy | 18.7 |
(NCT00132691)
Timeframe: 24 months
| Intervention | percentage of eyes with uveitis at risk (Number) |
|---|---|
| Flucinolone Acetonide Implant | 32.8 |
| Systemic Therapy | 6.3 |
(NCT00132691)
Timeframe: 24 months
| Intervention | percentage of eyes with uveitis at risk (Number) |
|---|---|
| Flucinolone Acetonide Implant | 26.2 |
| Systemic Therapy | 3.7 |
The percentage of subjects who used topical or systemic treatment for elevated IOP at any time during the 2 year follow-up and were not on IOP-lowering therapy at baseline is reported. (NCT00132691)
Timeframe: 24 months
| Intervention | percentage of eyes with uveitis at risk (Number) |
|---|---|
| Flucinolone Acetonide Implant | 61.1 |
| Systemic Therapy | 20.1 |
center point macular thickness >= 240 micrometers assessed on OCT (Stratus OCT-3 [Carl Zeiss Meditec, Dublin, CA]) as graded by Central Reading Center (NCT00132691)
Timeframe: 24 months
| Intervention | percentage of eyes with uveitis (Number) |
|---|---|
| Flucinolone Acetonide Implant | 22 |
| Systemic Therapy | 30 |
(NCT00132691)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Flucinolone Acetonide Implant | 1.6 |
| Systemic Therapy | 0 |
Uveitis activity was determined by clinician assessment at each study visit. The study ophthalmologist evaluated each eye as active, inactive/never had uveitis or cannot assess. (NCT00132691)
Timeframe: 24 months
| Intervention | percentage of eyes with uveitis (Number) |
|---|---|
| Fluocinolone Acetonide Implant | 12 |
| Systemic Therapy | 29 |
2 reviews available for prednisone and Panuveitis
| Article | Year |
|---|---|
Ocular inflammatory disease in patients with polymyalgia rheumatica: A case series and review of the literature.
Topics: Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Panuveitis; Polymyalgia Rheumatica; Pred | 2016 |
Ichthyosiform sarcoidosis: A case report and review of the literature.
Topics: Antibodies, Antinuclear; Biopsy; Dermatologic Agents; Female; Granuloma; Humans; Hypercalcemia; Icht | 2010 |
4 trials available for prednisone and Panuveitis
20 other studies available for prednisone and Panuveitis
| Article | Year |
|---|---|
IgA Nephropathy-Associated Uveitis: A Case Presentation.
Topics: Administration, Oral; Adult; Female; Fluorescein Angiography; Glomerulonephritis, IGA; Glucocorticoi | 2020 |
[Severe panuveitis in a metastatic cutaneous melanoma patient treated with vemurafenib].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Huma | 2018 |
Post-Streptococcal Uveitis: Case Report.
Topics: Administration, Oral; Dose-Response Relationship, Drug; Female; Fluorescein Angiography; Fundus Ocul | 2019 |
Oral corticosteroid exposure and increased risk of related complications in patients with noninfectious intermediate, posterior, or panuveitis: Real-world data analysis.
Topics: Administration, Oral; Data Analysis; Dose-Response Relationship, Drug; Drug-Related Side Effects and | 2019 |
Success with single-agent immunosuppression for multifocal choroidopathies.
Topics: Adolescent; Adult; Aged; Azathioprine; Chorioretinitis; Choroiditis; Drug Therapy, Combination; Elec | 2014 |
Long-lasting uveitis remission and hearing loss recovery after rituximab in Vogt-Koyanagi-Harada disease.
Topics: Administration, Oral; Adolescent; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; | 2015 |
Idiopathic Orbital Inflammation Presenting with Bilateral Panuveitis.
Topics: Adolescent; Fluorescein Angiography; Glucocorticoids; Humans; Magnetic Resonance Imaging; Male; Orbi | 2016 |
Long-term Management of Panuveitis and Iris Heterochromia in an Ebola Survivor.
Topics: Administration, Oral; Adult; Amides; Atropine; Drug Combinations; Ebolavirus; Eye Infections, Viral; | 2016 |
Rosai-Dorfman disease simulating nodular scleritis and panuveitis.
Topics: Diagnosis, Differential; Female; Histiocytes; Histiocytosis, Sinus; Humans; Immunoenzyme Techniques; | 2011 |
[Bilateral chronic and granulomatous total uveitis following cutaneous leishmaniasis].
Topics: Adolescent; Anti-Inflammatory Agents; Antiprotozoal Agents; Female; Granuloma; Humans; Leishmaniasis | 2011 |
Sweet's syndrome with panuveitis resembling Behçet's disease.
Topics: Behcet Syndrome; Betamethasone; Diagnosis, Differential; Fluorescein Angiography; Glucocorticoids; H | 2012 |
Levofloxacin-associated panuveitis with chorioretinal lesions.
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Bites and Stings; Female; | 2012 |
Tocilizumab treatment for recalcitrant uveitic macular edema.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Drug Therapy, Combination; Female; Glucocor | 2013 |
[Therapeutical difficulties in a patient with TB panuveitis and open angle glaucoma].
Topics: Adult; Anti-Inflammatory Agents; Antihypertensive Agents; Antitubercular Agents; Drug Therapy, Combi | 2002 |
Atypical presentation of multiple evanescent white dot syndrome involving granular lesions of varying size.
Topics: Adult; Choroid; Female; Fluorescein Angiography; Glucocorticoids; Humans; Optic Disk; Panuveitis; Pr | 2005 |
Optic neuropathy complicating multifocal choroiditis and panuveitis.
Topics: Adult; Choroiditis; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; | 2007 |
Diagnosis of limited ophthalmic Wegener granulomatosis: distinctive pathologic features with ANCA test confirmation.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Antineutrophil Cytoplasmic; Cyclophosphamide; Dacryocyst | 2008 |
Bilateral red eyes in a patient infected with human immunodeficiency virus.
Topics: AIDS-Related Opportunistic Infections; Diagnosis, Differential; Eye Infections, Bacterial; HIV Serop | 1995 |
Panuveitis and multifocal retinitis in a patient with leucocytoclastic vasculitis.
Topics: Adrenal Cortex Hormones; Delayed-Action Preparations; Female; Humans; Injections; Middle Aged; Panuv | 1993 |
Tuberculin skin-test-induced uveitis in the absence of tuberculosis.
Topics: Adolescent; Female; Fluorescein Angiography; Fundus Oculi; Humans; Panuveitis; Prednisone; Retinal D | 1991 |